These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 8758674)

  • 41. Changes in pulmonary mechanics after the administration of surfactant to infants with respiratory distress syndrome.
    Davis JM; Veness-Meehan K; Notter RH; Bhutani VK; Kendig JW; Shapiro DL
    N Engl J Med; 1988 Aug; 319(8):476-9. PubMed ID: 3405254
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Randomized European multicenter trial of surfactant replacement therapy for severe neonatal respiratory distress syndrome: single versus multiple doses of Curosurf.
    Speer CP; Robertson B; Curstedt T; Halliday HL; Compagnone D; Gefeller O; Harms K; Herting E; McClure G; Reid M
    Pediatrics; 1992 Jan; 89(1):13-20. PubMed ID: 1727997
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Effect of a bovine surfactant in very low birth weight premature infants with congenital pneumonia].
    Gortner L; Pohlandt F; Bartmann P
    Monatsschr Kinderheilkd; 1990 May; 138(5):274-8. PubMed ID: 2377170
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A prospective observational pilot study of synchronized nasal intermittent positive pressure ventilation (SNIPPV) as a primary mode of ventilation in infants > or = 28 weeks with respiratory distress syndrome (RDS).
    Santin R; Brodsky N; Bhandari V
    J Perinatol; 2004 Aug; 24(8):487-93. PubMed ID: 15141265
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhaled nitric oxide in the management of preterm infants with severe respiratory failure.
    Su PH; Chen JY
    J Perinatol; 2008 Feb; 28(2):112-6. PubMed ID: 17989696
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Variables associated with the early failure of nasal CPAP in very low birth weight infants.
    Ammari A; Suri M; Milisavljevic V; Sahni R; Bateman D; Sanocka U; Ruzal-Shapiro C; Wung JT; Polin RA
    J Pediatr; 2005 Sep; 147(3):341-7. PubMed ID: 16182673
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Very low birth weight infants--mortality and predictive risk factors.
    Chye JK; Lim CT
    Singapore Med J; 1999 Sep; 40(9):565-70. PubMed ID: 10628243
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Randomized controlled trial of exogenous surfactant for the treatment of hyaline membrane disease.
    Gitlin JD; Soll RF; Parad RB; Horbar JD; Feldman HA; Lucey JF; Taeusch HW
    Pediatrics; 1987 Jan; 79(1):31-7. PubMed ID: 3540835
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Perspectives on respiratory distress syndrome of the newborn.
    Polak MJ; Polak JD; Bucciarelli RL
    Compr Ther; 1989 Dec; 15(12):28-34. PubMed ID: 2691189
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Functional residual capacity and static compliance during the first year in preterm infants treated with surfactant.
    de Winter JP; Merth IT; Brand R; Quanjer PH
    Am J Perinatol; 2000; 17(7):377-84. PubMed ID: 12141525
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of exogenous surfactant therapy on levels of pulmonary surfactant proteins A and D in preterm infants with respiratory distress syndrome.
    Bae YM; Bae CW; Oh MH; Lee SH; Woo KM; Jung KB
    J Perinat Med; 2009; 37(5):561-4. PubMed ID: 19492923
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Effect of 2 different dosages of a porcine surfactant on pulmonary gas exchange of premature infants with severe respiratory distress syndrome].
    Herting E; Tubman R; Halliday HL; Harms K; Speer CP; Curstedt T; Robertson B
    Monatsschr Kinderheilkd; 1993 Sep; 141(9):721-7. PubMed ID: 8413348
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Surfactant replacement in neonates with early chronic lung disease.
    Pandit PB; Dunn MS; Kelly EN; Perlman M
    Pediatrics; 1995 Jun; 95(6):851-4. PubMed ID: 7761208
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Functional residual capacity and compliance of the respiratory system after surfactant treatment in premature infants with severe respiratory distress syndrome.
    Dinger J; Töpfer A; Schaller P; Schwarze R
    Eur J Pediatr; 2002 Sep; 161(9):485-90. PubMed ID: 12200607
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of surfactant replacement therapy on the outcome of premature infants with respiratory distress syndrome.
    Dolfin T; Zamir C; Regev R; Ben Ari J; Wolach B
    Isr J Med Sci; 1994 Apr; 30(4):267-70. PubMed ID: 8175327
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Flow-synchronized ventilation of preterm infants with respiratory distress syndrome.
    Donn SM; Nicks JJ; Becker MA
    J Perinatol; 1994; 14(2):90-4. PubMed ID: 8014707
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Surfactant replacement therapy: impact on hospital charges for premature infants with respiratory distress syndrome.
    Maniscalco WM; Kendig JW; Shapiro DL
    Pediatrics; 1989 Jan; 83(1):1-6. PubMed ID: 2909956
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical course of premature infants intubated in the delivery room, submitted or not to porcine-derived lung surfactant therapy within the first hour of life.
    Lefort S; Diniz EM; Vaz FA
    J Matern Fetal Neonatal Med; 2003 Sep; 14(3):187-96. PubMed ID: 14694974
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Surfactant therapy in severe neonatal respiratory failure--multicenter study--I. Surfactant therapy in 264 premature infants of < 34 weeks with IRDS with special reference to "non-responders"].
    Ebbecke K; Jorch G
    Klin Padiatr; 1993; 205(2):71-5. PubMed ID: 8487483
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Respiratory distress syndrome in the newborn: innovative therapies.
    Wiswell TE; Mendiola J
    Am Fam Physician; 1993 Feb; 47(2):407-14. PubMed ID: 8430594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.